Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer.
Mirallié E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, Faivre-Chauvet A, Murat A, Charbonnel B, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodéré F. Mirallié E, et al. Among authors: vuillez jp. J Clin Endocrinol Metab. 2005 Feb;90(2):779-88. doi: 10.1210/jc.2004-1500. Epub 2004 Nov 30. J Clin Endocrinol Metab. 2005. PMID: 15572422
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J; French Endocrine Tumor Group. Chatal JF, et al. Among authors: vuillez jp. J Clin Oncol. 2006 Apr 10;24(11):1705-11. doi: 10.1200/JCO.2005.04.4917. Epub 2006 Mar 20. J Clin Oncol. 2006. PMID: 16549819 Clinical Trial.
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallié E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodéré F. Oudoux A, et al. Among authors: vuillez jp. J Clin Endocrinol Metab. 2007 Dec;92(12):4590-7. doi: 10.1210/jc.2007-0938. Epub 2007 Sep 18. J Clin Endocrinol Metab. 2007. PMID: 17878252 Clinical Trial.
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Salaun PY, Campion L, Bournaud C, Faivre-Chauvet A, Vuillez JP, Taieb D, Ansquer C, Rousseau C, Borson-Chazot F, Bardet S, Oudoux A, Cariou B, Mirallié E, Chang CH, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J, Kraeber-Bodéré F. Salaun PY, et al. Among authors: vuillez jp. J Nucl Med. 2012 Aug;53(8):1185-92. doi: 10.2967/jnumed.111.101865. Epub 2012 Jun 28. J Nucl Med. 2012. PMID: 22743249 Free article. Clinical Trial.
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
Kraeber-Bodéré F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, Ferreira TC, Bardiès M, Ferrer L, Resche I, Gautherot E, Rouvier E, Barbet J, Chatal JF. Kraeber-Bodéré F, et al. Among authors: vuillez jp. Clin Cancer Res. 1999 Oct;5(10 Suppl):3190s-3198s. Clin Cancer Res. 1999. PMID: 10541363 Clinical Trial.
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardiès M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Among authors: vuillez jp. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3973S-81S. Clin Cancer Res. 2003. PMID: 14506196 Clinical Trial.
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Among authors: vuillez jp. J Nucl Med. 2006 Feb;47(2):247-55. J Nucl Med. 2006. PMID: 16455630 Free article. Clinical Trial.
¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.
Salaun PY, Campion L, Ansquer C, Frampas E, Mathieu C, Robin P, Bournaud C, Vuillez JP, Taieb D, Rousseau C, Drui D, Mirallié E, Borson-Chazot F, Goldenberg DM, Chatal JF, Barbet J, Kraeber-Bodéré F. Salaun PY, et al. Among authors: vuillez jp. Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1501-10. doi: 10.1007/s00259-014-2772-0. Epub 2014 May 8. Eur J Nucl Med Mol Imaging. 2014. PMID: 24806110 Clinical Trial.
Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
Vuillez JP, Kraeber-Bodéré F, Moro D, Bardiès M, Douillard JY, Gautherot E, Rouvier E, Barbet J, Garban F, Moreau P, Chatal JF. Vuillez JP, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3259s-3267s. Clin Cancer Res. 1999. PMID: 10541373 Clinical Trial.
86 results